[{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Berenberg","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"Aspirin","moa":"COX-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hyloris Pharmaceuticals \/ Berenberg","highestDevelopmentStatusID":"6","companyTruncated":"Hyloris Pharmaceuticals \/ Berenberg"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Berenberg","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"Aspirin","moa":"COX-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hyloris Pharmaceuticals \/ Berenberg","highestDevelopmentStatusID":"6","companyTruncated":"Hyloris Pharmaceuticals \/ Berenberg"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : DSR 2.0 therapy involves the use of the peritoneal cavity for the removal of sodium via diffusion. The body responds by eliminating the associated fluid via osmotic ultrafiltration or urination. It is being investigated for congestive heart failure.

                          Product Name : DSR 2.0

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 03, 2023

                          Lead Product(s) : Icodextrin

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : Hyloris currently envisages using the net proceeds of the offering to primarily fund the development of additional new product candidates including HY-073 and accelerate in-house R&D activities, including repurposing and analytical expertise.

                          Product Name : HY-073

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          March 31, 2022

                          Lead Product(s) : Aspirin

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Berenberg

                          Deal Size : $16.3 million

                          Deal Type : Private Placement

                          blank

                          03

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : Hyloris will use the net proceeds of the Offering primarily to fund the development of new products and accelerate in-house R&D activities including HY-073 (IV acetylsalicylic acid).

                          Product Name : HY-073

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 04, 2022

                          Lead Product(s) : Aspirin

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Berenberg

                          Deal Size : $16.2 million

                          Deal Type : Private Placement

                          blank